Aarey Drugs & Pharmaceuticals Ltd. (BSE: 524412) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹321 Cr, it ranks #2,288 by market cap among the 6,137 Indian listed companies on FinBizNet, and #54 of 86 in Medicinal Chemicals and Botanical Products. At ₹106.73 (as of 25 Oct 2026), the share price is 7.0% below its 52-week high of ₹114.80 and 112.1% above its 52-week low of ₹50.31. The share price is up 22.9% over one year and up 37.7% over three months.
| Current Price | ₹106.73 |
|---|---|
| Market Cap | ₹321 Cr |
| BSE Code | 524412 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 81.8 |
| Return on Equity | 2.75% |
| Return on Assets | 1.23% |
| 52-Week Range | ₹50.31 – ₹114.80 |
| 1-Year Price Change | +22.9% |
| 3-Month Price Change | +37.7% |
| Beta (1Y) | 0.85 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.aareydrugs.com |
| Revenue | ₹45 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 2.3% |
| EPS (Basic) | ₹0.36 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company offers intermediates, including mono methyl urea, di methyl urea, ortho para nitro anisole, 2-bromomethyl-1,3-dioxolane, and uracil. It also provides active pharmaceutical ingredients, such as metformin HCl, mefenamic acid, and doxofylline. In addition, the company trades chemicals and solvents, including aromatic chemicals, chemical acids, chlor-alkali, glycols and glycol ethers, fiber intermediates, and acetates and esters, as well as industrial alcohols, ketones, amines, oleochemicals, intermediates, olefins, phosphates, fertilizers, monomers, and chemicals. It serves pharmaceutical formulation manufacturers and pharmaceutical merchant exporters. Aarey Drugs & Pharmaceuticals Limited was incorporated in 1990 and is headquartered in Mumbai, India.
1. Trading and Manufacturing Activities-This segment engages in the manufacture and supply of pharmaceutical raw materials, chemicals, pharmaceuticals ingredients, food colours, and flavours.
1. Trading and Manufacturing Activities-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Aarey Drugs & Pharmaceuticals Ltd. | ₹321 Cr | 81.8 | 2.75% | ₹45 Cr | +22.9% |
Listed by market capitalisation. Ratios are shown for context only.
Aarey Drugs & Pharmaceuticals Ltd. is trading at ₹106.73, with a market capitalisation of ₹321 Cr.
Aarey Drugs & Pharmaceuticals Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Aarey Drugs & Pharmaceuticals Ltd. has a P/E of 81.8 and a return on equity of 2.75%.
Aarey Drugs & Pharmaceuticals Ltd. is listed on the BSE under the scrip code 524412.
Aarey Drugs & Pharmaceuticals Ltd.'s share price is up 22.9% over one year and up 37.7% over three months. Its 52-week range is ₹50.31 to ₹114.80.
In Q1 FY27, Aarey Drugs & Pharmaceuticals Ltd. reported revenue of ₹45 Cr and net profit of ₹1 Cr, with basic EPS of ₹0.36 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.